- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 13.01. | Orchestra BioMed to pick up $21M through Haemonetics' acquisition of Vivasure | 2 | MassDevice | ||
| 12.01. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Assessing Orchestra BioMed Holdings: Insights From 4 Financial Analysts | 1 | Benzinga.com | ||
| 10.12.25 | TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio | 1 | Investing.com | ||
| 08.12.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | 142 | GlobeNewswire (Europe) | Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension... ► Artikel lesen | |
| 26.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.11.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews | ||
| 10.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | 187 | GlobeNewswire (Europe) | Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital... ► Artikel lesen | |
| 10.11.25 | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | Orchestra BioMed files secondary offering of ~8M shares | 2 | Seeking Alpha | ||
| 28.10.25 | Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB | 5 | RTTNews | ||
| 28.10.25 | Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement | 2 | MassDevice | ||
| 28.10.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10.25 | Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial | 1 | MassDevice | ||
| 27.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial | 261 | GlobeNewswire (Europe) | Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release... ► Artikel lesen | |
| 09.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | 2 | GlobeNewswire (USA) | ||
| 11.09.25 | Piper Sandler reiterates Overweight rating on Orchestra BioMed stock | 3 | Investing.com | ||
| 11.09.25 | Piper Sandler bestätigt "Overweight"-Rating für Orchestra BioMed | - | Investing.com Deutsch | ||
| 04.09.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | +0,01 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,08 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab | ||
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,58 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ADMA BIOLOGICS | 17,300 | +1,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,43 % bei einem Aktienkurs von 3,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.